An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma

Respiratory Medicine

Volumn 98, Issue 11, 2004, Pages 1146-1154

  Jönsson, Bengt ^a   Berggren, Fredrik ^b   Svensson, Klas ^c   O'Byrne, Paul M ^d  

^a STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Budesonide; Economic evaluation; Formoterol; Mild to moderate asthma

Indexed keywords

BECLOMETASONE DIPROPIONATE; BECLOMETASONE DIPROPIONATE PLUS SALBUTAMOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; FORMOTEROL; MONTELUKAST; PREDNISOLONE; SALBUTAMOL; SALMETEROL XINAFOATE; TERBUTALINE; THEOPHYLLINE;

ABSENTEEISM; ARTICLE; ASTHMA; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG USE; ECONOMIC EVALUATION; HEALTH PRACTITIONER; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEDEN; SYMPTOMATOLOGY;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COSTS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; MIDDLE AGED; SICK LEAVE;

EID: 4844224532     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2004.04.005     Document Type: Article

References (26)

1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention: WHO/NHLBI Workshop report. National Institutes of Health, National Heart, Lung and Blood Institute. Publication Number 02-3659, 2002.
2. O'Byrne P. Cuddy L. Taylor D.W. Birch S. Morris J. Syrotuik J. Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice Can Respir J 3 1996 169-175
3. O'Byrne P.M. Barnes P.J. Rodriguez-Roisin R. et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial Am J Respir Crit Care Med 164 2001 1392-1397
4. Hoskins G. McCowan C. Neville R.G. Thomas G.E. Smith B. Silverman S. Risk factors and costs associated with an asthma attack Thorax 55 2000 19-24
5. Jacobson L. Hertzman P. Löfdahl C.G. Skoogh B.E. Lindgren B. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991 Respir Med 94 2000 247-255
6. Weiss K.B. Sullivan S.D. The health economics of asthma and rhinitis. I. Assessing the economic impact J Allergy Clin Immunol 107 2001 3-8
7. Haahtela T. Jarvinen M. Kava T. et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma N Engl J Med 331 1994 700-705
8. Bukstein D.A. Luskin A.T. Bernstein A. "Real-world" effectiveness of daily controller medicine in children with mild persistent asthma Ann Allergy Asthma Immunol 90 2003 543-549
9. Gerdtham U.G. Hertzman P. Jönsson B. Boman G. Impact of inhaled corticosteroids on acute asthma hospitalization in Sweden 1978 to 1991 Med Care 34 1996 1188-1198
10. Pauwels R.A. Löfdahl C.G. Postma D.S. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma N Engl J Med 337 1997 1405-1411
11. Andersson F. Ståhl E. Barnes P.J. et al. Adding formoterol to budesonide in moderate asthma-health economic results from the FACET study Respir Med 95 2001 505-512
12. Sullivan S. Elixhauser A. Buist S. Luce B.R. Eisenberg J. Weiss K.B. National Asthma Education and Prevention Program Working Group Report on the cost-effectiveness of asthma care Am J Respir Crit Care Med 154 1996 S84-S95
13. Landstingsförbundet (Swedish Federation of County Councils), 1997, Kostnad per intagen patient, vårddag mm 1996 (Costs per hospitalized patient per day of care), Landstingsförbundet (Swedish Federation of County Councils), 1999.
14. Personal communication, Landstingsförbundet (Swedish Federation of County Councils), 1997.
15. Hjortsberg C. Svarvar P. IHE arbetsrapport (Working Paper). Lund: The Swedish Institute for Health Economics; 1999. p. 2.
16. Läkarförbundet (Swedish Medical Association), 1998.
17. SACO (Swedish Confederation of Professional Associations), 1999.
18. FASS, Läkemedel i Sverige (Swedish Drug Catalogue), 1999, Kungsbacka, Linfo, Läkemedelsinformation AB.
19. Lönestatistisk årsbok 1998 (Wage Statistics for 1998), SCB (Statistics Sweden), 1999.
20. Weinstein M.C. Principles of cost-effective resource allocation in health care organizations Int J Technol Assess Health Care 6 1990 93-103
21. Paltiel A.D. Fuhlbrigge A.L. Kitch B.T. et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model J Allergy Clin Immunol 108 2001 39-46
22. Janson S. Reed M.L. Patients' perceptions of asthma control and impact on attitudes and self-management J Asthma 37 2000 625-640
23. Juniper E.F. Using humanistic health outcomes data in asthma Pharmacoeconomics 19 Suppl. 2 2001 13-19
24. Sullivan S.D. Liljas B. Buxton M. Lamm C.J. O'Byrne P. Tan W.C. Weiss K.B. Design and analytic considerations in determining the cost-effectiveness of early intervention in asthma from a multinational clinical trial Controlled Clin Trials 22 2001 420-437
25. Sullivan S.D. Buxton M. Andersson F.L. Lamm C.J. Liljas B. Chen Y.Z. Pauwels R.A. Weiss K.B. Cost-effectiveness analysis of early intervention with budesonide in asthma J Allergy Clin Immunol 112 2003 1229-1236
26. Oostenbrink J.B. Rutten-van Molken M.P. Methods to analyse cost data of patients who withdraw in a clinical trial setting Pharmacoeconomics 21 2003 1103-1112